AR098997A2 - Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación - Google Patents

Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Info

Publication number
AR098997A2
AR098997A2 ARP140104956A ARP140104956A AR098997A2 AR 098997 A2 AR098997 A2 AR 098997A2 AR P140104956 A ARP140104956 A AR P140104956A AR P140104956 A ARP140104956 A AR P140104956A AR 098997 A2 AR098997 A2 AR 098997A2
Authority
AR
Argentina
Prior art keywords
dosage unit
constipation
analogue
analog
suitable excipient
Prior art date
Application number
ARP140104956A
Other languages
English (en)
Inventor
Ueno Ryuji
L Patchen Myra
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098997(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR098997A2 publication Critical patent/AR098997A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Se describe una unidad de dosificación para tratar la constipación en un paciente humano. La unidad de dosificación comprende un análogo de prostaglandina halogenado y un excipiente farmacéuticamente adecuado. La unidad de dosificación alivia la constipación sin efectos colaterales sustanciales. Reivindicación 1: Una unidad de dosificación para usar con el fin de aliviar o prevenir la constipación en un paciente humano que comprende un análogo de prostaglandina (PG) representado por la fórmula (1) y/o sus tautómeros, y un excipiente farmacéuticamente adecuado, caracterizada porque la unidad de dosificación contiene dicho análogo de PG en el rango de aprox. 6 - 96 mg; en donde A¹ y A² son átomos de halógeno iguales o diferentes y B es -COOH, incluyendo sus sales, ésteres o amidas farmacéuticamente aceptables. Reivindicación 3: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho análogo de PG está presente en el rango de aprox. 24 - 72 mg. Reivindicación 7: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho excipiente farmacéuticamente adecuado es un ácido graso de cadena mediana.
ARP140104956A 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación AR098997A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
AR098997A2 true AR098997A2 (es) 2016-06-22

Family

ID=23293447

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Country Status (14)

Country Link
US (3) US8097653B2 (es)
EP (2) EP1443938B1 (es)
JP (2) JP4852229B2 (es)
AR (3) AR037524A1 (es)
AT (1) ATE522218T1 (es)
BR (1) BR0214075A (es)
CA (1) CA2464420C (es)
CY (1) CY1115856T1 (es)
DK (2) DK1443938T3 (es)
ES (2) ES2368729T3 (es)
LU (1) LU92826I2 (es)
PT (2) PT2298314E (es)
TW (1) TWI331920B (es)
WO (1) WO2003041716A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
RU2420291C3 (ru) * 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
EP0978284B1 (en) 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
JP4183943B2 (ja) 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
JP4852229B2 (ja) 2012-01-11
JP2011201905A (ja) 2011-10-13
DK1443938T3 (da) 2011-09-26
TW200300091A (en) 2003-05-16
US20130143958A1 (en) 2013-06-06
EP1443938A1 (en) 2004-08-11
AR037524A1 (es) 2004-11-17
JP2005513014A (ja) 2005-05-12
WO2003041716A1 (en) 2003-05-22
LU92826I2 (fr) 2015-11-24
BR0214075A (pt) 2004-09-28
PT1443938E (pt) 2011-09-27
ATE522218T1 (de) 2011-09-15
US8097653B2 (en) 2012-01-17
US20120088824A1 (en) 2012-04-12
CY1115856T1 (el) 2017-01-25
ES2524369T3 (es) 2014-12-05
EP1443938B1 (en) 2011-08-31
EP2298314B1 (en) 2014-09-03
CA2464420A1 (en) 2003-05-22
HK1155649A1 (en) 2012-05-25
US20030119898A1 (en) 2003-06-26
DK2298314T3 (en) 2014-12-01
CA2464420C (en) 2011-12-13
US8389542B2 (en) 2013-03-05
PT2298314E (pt) 2014-12-03
AR117404A2 (es) 2021-08-04
TWI331920B (en) 2010-10-21
EP2298314A1 (en) 2011-03-23
ES2368729T3 (es) 2011-11-21

Similar Documents

Publication Publication Date Title
SE0202462D0 (sv) Novel use
ES2086270T3 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
UY26782A1 (es) Derivados del benzotiazol
CO5180579A1 (es) Composicion oral solida que comprende levidopa, carbidopa y entacapone
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
NO20024772D0 (no) Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel
ES2160693T3 (es) Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona.
SE0202429D0 (sv) Novel Compounds
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
SE0102440D0 (sv) New compound
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE50213137D1 (de) Arzneimittel zur behandlung von viralen haut- und tumorerkrankungen
AR037427A1 (es) Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento
NO975726L (no) N-Hydroksyurea-derivater som anti-inflammatoriske midler
ATE393152T1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
NO20031678L (no) Profylaktisk og terapeutisk middel for diabetiske komplikasjoner

Legal Events

Date Code Title Description
FB Suspension of granting procedure